Dalbavancin (MDL-63397) 是一種半合成的脂糖肽抗生素，對革蘭氏陽性細菌具有有效的殺菌活性。Dalbavancin 抑制金黃色葡萄球菌和炭疽芽孢桿菌的 MIC90 分別為 0.06 μg/mL 和 0.25 μg/mL。

Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2].

Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1].